Archives
-
Isradipine: Calcium Channel Research Context
2026-10-06
Isradipine (Dynacirc) is a dihydropyridine calcium channel blocker whose research relevance centers on L-type channel pharmacology, vascular smooth muscle relaxation, and hypotheses involving neuronal calcium dysregulation. This overview compares the supplied product description with evidence from Sidach and Mintz on calcium-channel pharmacology, emphasizing what can—and cannot—be inferred about neuroprotection, hypertension research, and neurodegenerative disease models.
-
Itraconazole and Candida Biofilm Resistance: Evidence
2026-10-05
This source-grounded overview examines itraconazole as a triazole antifungal agent in the context of Candida biofilm resistance, PP2A-regulated autophagy, and antifungal drug interaction studies. The available 2025 study provides mechanistic evidence that PP2A-associated autophagy influences Candida albicans biofilm formation and treatment response, but it does not establish an itraconazole-specific mechanism. Supplier-reported properties, including antifungal activity against Candida glabrata, CYP3A4 interaction, angiogenesis inhibition, and hedgehog pathway effects, therefore require separate validation and should not be treated as findings from the biofilm study.
-
PP2A, Autophagy, and Candida Biofilm Resistance
2026-10-05
Shen et al. connect the PP2A catalytic subunit PPH21 with autophagy regulation, biofilm formation, and antifungal resistance in Candida albicans. The study combines genetic, cellular, and mouse-model evidence, while its conclusions remain bounded by the oral infection setting and the need for further validation of the proposed phosphorylation pathway.
-
7-dehydro Cholesterol: Five Evidence Questions
2026-10-04
A source-grounded overview of 7-dehydro Cholesterol, DHCR7 biology, and a 2026 grass carp study linking Dhcr7 disruption with resistance to grass carp reovirus. It separates reported findings from interpretation and clarifies what the evidence does—and does not—show.
-
Galectin-1, FIP200, and Hepatic Steatosis
2026-10-03
A 2026 study identifies a Galectin-1–FIP200 interaction as an upstream mechanism linking impaired autophagy with hepatic steatosis, dyslipidemia, and insulin resistance. Its mouse, proteomic, interaction-mapping, and mutational evidence supports a new mechanistic model for NAFLD, while remaining limited to preclinical systems.
-
Epalrestat and the Polyol Pathway: A Translational Lens
2026-10-02
Epalrestat offers a mechanistically grounded way to interrogate aldose reductase, polyol pathway flux, and oxidative stress across diabetic complication, neurodegeneration, and emerging cancer-metabolism research. This article connects the compound’s established pathway logic with the 2025 Cancer Letters review on fructose metabolism while distinguishing evidence-based opportunity from hypothesis requiring validation.
-
Sulfaphenazole Workflows for CYP2C9 Research
2026-10-01
Sulfaphenazole enables controlled CYP2C9 inhibition assays while also supporting studies of endothelial dysfunction, oxidative stress, wound repair, and antimycobacterial activity. This practical guide connects concentration selection, solvent handling, perfusion readouts, and troubleshooting to help researchers design more interpretable experiments.
-
Pam3CSK4: Mapping TLR1/2–Neural Inflammation
2026-10-01
Pam3CSK4 is a defined TLR1/2 agonist for dissecting innate immune activation, macrophage responses, and allergic inflammation. This article presents a causal assay framework that separates direct TLR signaling from the neuroimmune mechanisms described in recent TRPV1 research.
-
Oltipraz Workflows for Nrf2 and MASLD
2026-09-30
Use Oltipraz as a chemically defined Nrf2 benchmark to connect phase II enzyme induction with lipid stress, autophagy, and ferroptosis in MASLD research. Its controlled composition complements complex botanical interventions by separating Nrf2-dependent effects from multi-component treatment responses.
-
(S)-Mephenytoin: CYP2C19 Assay Guide
2026-09-30
This scenario-driven guide explains how (S)-Mephenytoin, SKU C3414, can support controlled CYP2C19 and pharmacokinetic studies alongside cell viability or cytotoxicity workflows. It covers solvent selection, organoid compatibility, kinetic interpretation, storage, and practical vendor-selection criteria.
-
Pravastatin sodium Assay Workflows
2026-09-29
Pravastatin sodium adds a mechanistic HMG-CoA reductase inhibitor control to macrophage cholesterol, hepatocyte safety, and botanical-interaction assays. This guide connects cholesterol biosynthesis inhibition with transporter-aware workflows, practical dose planning, and troubleshooting decisions that separate target engagement from nonspecific cytotoxicity.
-
MSC–NRF2–ATF4 Signaling in Pancreatic Cancer
2026-09-29
This 2026 study shows that Se-methylselenocysteine elicits phenotype-dependent NRF2, ATF4, and ferroptosis-associated responses in pancreatic ductal adenocarcinoma cells. Its findings identify KYAT1-dependent metabolic activation, rather than compound exposure alone, as a key determinant of redox remodeling and suggest practical ways to distinguish adaptive stress signaling from iron-dependent cytotoxicity.
-
Danazol in HPG-Axis Research Workflows
2026-09-28
Danazol and Danocrine provide a practical perturbation tool for studying steroidogenesis, hypothalamic–pituitary–gonadal signaling, and endocrine phenotypes. This workflow translates a recent rat-model study into formulation guidance, assay design, troubleshooting, and comparative applications.
-
7-dehydro Cholesterol: From Sterol Flux to Immunity
2026-09-28
7-dehydro Cholesterol sits at the intersection of cholesterol biosynthesis, UVB-driven vitamin D3 formation, and oxidation-sensitive lipid biology. A 2026 grass carp study adds an important in vivo dimension: disrupting dhcr7 was associated with stronger antiviral responses and improved survival after GCRV-II challenge. This article considers what the findings establish, what remains uncertain, and how researchers can design rigorous sterol-perturbation studies without overextending cross-species conclusions.
-
DIDS Workflows for Tumor Stress and Ion Transport
2026-09-27
Use DIDS to probe anion transport and to design controlled studies of cell survival after near-lethal stress—two applications that require different controls and interpretations. This guide connects channel pharmacology with metastasis research while distinguishing published findings from practical starting conditions.